Results 211 to 220 of about 100,219 (301)

The Coronary Artery Changes and Complications Caused by Takotsubo Syndrome: A Review With Novel Observations. [PDF]

Rev Cardiovasc Med
Y-Hassan S.
europepmc   +1 more source

Numerical validation of the applicability of the simplified ventricular model in the analysis of hemolysis in the mitral paravalvular leak. [PDF]

Front Bioeng Biotechnol
Truchel K, Wojtas K, Marchel M, Orciuch W, Makowski Ł.   +4 more
europepmc   +1 more source

Isolated Diastolic Hypertension

The Journal of Clinical Hypertension, 2003
openaire   +3 more sources

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

Development and Validation of a Diagnostic Nomogram for Predicting Hypertension in Patients With Obstructive Sleep Apnea at High Altitude. [PDF]

Int J Hypertens
Shi W, Wang R, Liu D, Sun H, Qin Y, Du B, Zhang R, Tang H, Chu A.   +8 more
europepmc   +1 more source

Comparison of Parametric Mapping Indices in Systole versus Diastole Among a Cohort of Children Undergoing Sedated CMR

Hunter C. Wilson, Sassan Hashemi, Denver Sallee, Clayton A. Smith, Timothy C. Slesnick   +4 more
openalex   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Ketone Catabolism Is Essential for Maintaining Normal Heart Function During Aging. [PDF]

J Am Heart Assoc
Keller MA, Nakamura M.
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source